Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE C-Jun drives melanoma progression in PTEN wild type melanoma cells. 31378787 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Our data show that MAPKi-resistant melanoma cells acquire vulnerability to Notch signaling activation and suggest that Notch-c-JUN-EDN1 axis is a potential therapeutic target in MAPKi-resistant melanoma. 30614626 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Interestingly, JMJD6 is transcriptionally activated by c-Jun, generating a feedforward loop to drive the development and progression of melanoma. 29187213 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Deficiency of methylthioadenosine phosphorylase (MTAP) supports melanoma development and progression through accumulation of its substrate 5'-methylthioadenosine (MTA), which leads amongst others to a constitutive inhibition of protein arginine methyltransferases (PRMTs) and activation of the transcription factor AP-1 via the receptor ADORA2B. 27479139 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Consequently, we identified 44 direct c-Jun targets and a detailed analysis of 6 selected genes confirmed their deregulation in malignant melanoma. 27050748 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation. 27045082 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Gene expression data from a panel of melanoma cell lines and a patient cohort showed that JUN expression correlated with a mesenchymal gene signature, implicating c-JUN as a key mediator of the mesenchymal-like phenotype associated with drug resistance. 26286024 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE In summary, there are a variety of mechanisms underlying the induction of c-Jun protein expression and activity leading to tumor progression and development, and this diverse regulatory machinery is due to the heterogeneity of different tumor types, particularly in malignant melanoma. 24315690 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. 22797068 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE The transcription factor AP1 (activating protein 1), a heterodimer of the JUN and FOS proteins, promotes the invasive growth and metastasis of various tumors such as squamous cell carcinoma (SCC), breast cancer, and melanoma. 23633675 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Recently, we discovered that the loss of E-cadherin induces c-Jun protein expression, which is a member of the AP-1 transcription factor family and a key player in the processes of cell proliferation and tumor development and also found in elevated levels in melanomas. 21732343 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Hierarchical clustering analysis of the expression data was able to distinguish between the melanoma and nonmelanoma samples and further stratified the melanoma samples into two groups differentiated by high expression of the genes involved in beta-catenin activation (EGFR and WNT5A) and the MAPK/ERK pathway (BRAF, FOS, and JUN). 16116595 2005
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Loss of expression of the apoptosis protease activator protein-1 (APAF-1) in human melanoma is thought to promote resistance to programmed cell death by preventing caspase-9 activation. 15492260 2004
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Electrophoretic mobility shift analysis analyses have revealed an increase in binding activity of activator protein 1 (c-Jun) and nuclear factor-kappaB after DTIC treatment for both melanoma cell lines. 12939465 2003
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. 11251188 2001
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE We presently review the potential role of AP-1 proteins in differentiation with specific emphasis on melanoma differentiation. 9824619 1998